Tixagevimab-cilgavimab as an Early Treatment for COVID-19 in Kidney Transplant Recipients-Reference-Cited by-同舟云学术

Tixagevimab-cilgavimab as an Early Treatment for COVID-19 in Kidney Transplant Recipients

Published:2023-07-20 Issue:8 Volume:107 Page:e215-e218
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:

Author:

Benotmane Ilies¹²,Olagne Jérôme¹,Gautier-Vargas Gabriela¹,Cognard Noëlle¹,Heibel Françoise¹,Braun-Parvez Laura¹,Keller Nicolas¹,Martzloff Jonas¹,Perrin Peggy¹,Pszczolinski Romain¹,Moulin Bruno¹²,Fafi-Kremer Samira²³,Caillard Sophie¹²

Affiliation:

1. Department of Nephrology Dialysis and Transplantation, Strasbourg University Hospital, Strasbourg, France.

2. Inserm UMR S1109 Labex Transplantex, Fédération de Médecine Translationnelle, Strasbourg University, Strasbourg, France.

3. Department of Virology, Strasbourg University Hospital, Strasbourg, France.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference4 articles.

1. LB5. PROVENT: phase 3 study of efficacy and safety of AZD7442 (tixagevimab/cilgavimab) for pre-exposure prophylaxis of COVID-19 in adults.;Levin;Open Forum Infect Dis,2021

2. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.;Planas;Nat Commun,2023

3. Comparative pharmacokinetics of tixagevimab/cilgavimab (AZD7442) administered intravenously versus intramuscularly in symptomatic SARS-CoV-2 infection.;Bender Ignacio;Clin Pharmacol Ther,2022

4. Molecular evolution of the SARS-CoV-2 omicron BA.2 variant in kidney transplant recipients with prolonged viral shedding.;Caillard;J Infect,2023

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another?;Viruses;2024-02-29

2. Prior Infection Reduces Omicron COVID-19 Severity in Solid Organ Transplant Recipients;Transplantation;2024-01-31

3. Opportunities to improve the prognosis of the course of COVID-19 for at-risk patients;Terapevticheskii arkhiv;2023-10-11